Zydus launches Lenalidomide Capsules
News

Zydus launches Lenalidomide Capsules

Lenalidomide is used to treat various types of cancers.

  • By IPP Bureau | September 22, 2022

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) has launched Lenalidomide Capsules in the US. The company had earlier received final approvals for 5 mg, 10 mg, 15 mg and 25 mg strengths and tentative approvals for 2.5 mg and 20 mg strength. USRLD: Revlimid.

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). The drug is being manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India.

Lenalidomide had annual sales of USD 2.86 bn in the United States, according to IQVIA MAT July 2022.

Upcoming E-conference

Other Related stories

Startup

Digitization